A three-gene expression score for predicting clinical benefit to anti-PD-1 blockade in advanced renal cell carcinoma
In the advanced renal cell carcinoma (RCC) scenario, there are no consistent biomarkers to predict the clinical benefit patients derived from immune checkpoint blockade (ICB). Taking this into consideration, herein, we conducted a retrospective study i…